Also, ILK inhibition in colon cancer cells reduces tumor growth in mouse models and in vitro cell lines via reducing β-catenin nuclear expression and increasing GSK3β activity by phosphorylation reduction, resulting in β-catenin degradation (Tan et al., 2001). The gene discussed is ILK; the disease is malignant colon neoplasm.